Intas launches biosimilar Bevacizumab with aggressive pricin
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Bevacizumab a biosimilar spin-off of the cancer drug Avastin by Roche Pharma, used for treating several types of cancer including colorectal, lung and cervical cancer besides the certain form of brain tumors, has been launched by Intas Parma. The drug will be available in the market at Rs 39,995 for 400mg, which is 60% lower than the currently available treatment option. Intas would be sharing the Bevacizumab market with the likes of Zydus Cadila, Hetero and Reliance Lifesciences. The company through its pricing strategy will expand the market which currently serves only 5% of the patients.

Roche Avastin has objected the approval of the biosimilar version of these drugs on the grounds that the Indian drug controller did not follow due process while granting the approval. However, Intas claims that the company has followed all due process in getting the approval for the drug.

Roche Avastin had earlier made several attempts to stall biosimilar drug launches of its cancer drugs in a bid to ward off competition...

http://economictimes.indiatimes.com/industry/healthcare/biotech/intas-launches-biosimilar-bevacizumab-with-aggressive-pricing/articleshow/60942881.cms
Preview
Dr. B●●●l D●●●i and 1 others like this
Like
Comment
Share